Amidate

Etomidate is a non-barbiturate, carboxylated imidazole derivative used primarily as an intravenous general anesthetic for the induction of anesthesia and sedation for short procedures.

Dosage of Etomidate must be individualized based on the patient's weight, clinical condition, and the specific requirements of the procedure. It is administered strictly by the intravenous route.

• Induction of Anesthesia: The standard dose for the induction of anesthesia in adult patients ranges from 0.2 mg/kg to 0.6 mg/kg of body weight. For a typical 70 kg adult, this equates to 14 mg to 42 mg. The injection should be administered over a period of 30 to 60 seconds to minimize the risk of side effects like myoclonus (involuntary muscle twitching).
• Procedural Sedation: For shorter procedures, lower doses (e.g., 0.1 mg/kg to 0.15 mg/kg) may be utilized, often in combination with an analgesic.

Etomidate is approved for use in pediatric patients, but its use is generally reserved for those older than 10 years of age.

• Children (10 years and older): The dosage is similar to that of adults, typically 0.2 mg/kg to 0.3 mg/kg.
• Children (under 10 years): Safety and efficacy have not been established by the FDA for patients under 10. However, in emergency medicine, it is sometimes used off-label by specialists at similar weight-based doses, though caution is required due to the potential for more pronounced adrenal suppression in younger children.

Renal Impairment

Specific dosage adjustments for renal (kidney) impairment are not formally defined in the manufacturer's labeling, as the primary metabolite is inactive. However, because the drug is highly protein-bound and uremia (buildup of toxins in the blood) can alter protein binding, clinicians often use the lower end of the dosing range and monitor the patient closely.

Hepatic Impairment

In patients with cirrhosis or severe hepatic (liver) impairment, the volume of distribution can be increased, and the clearance of Etomidate may be reduced. This can lead to a prolonged duration of action. A dose reduction or slower administration rate is often necessary.

Elderly Patients

Geriatric patients (aged 65 and older) are generally more sensitive to the hypnotic effects of Etomidate. They often have a smaller initial volume of distribution and slower clearance. Healthcare providers typically reduce the starting dose (e.g., 0.15 mg/kg to 0.2 mg/kg) and titrate carefully to avoid excessive sedation or respiratory depression.

Etomidate is not a medication that a patient takes at home. It is administered in a hospital or clinical setting by an anesthesiologist, CRNA, or emergency physician.

• Preparation: The medication is drawn into a syringe and should be inspected for particulate matter or discoloration. It should not be mixed with other medications in the same syringe.
• Administration: It is injected through a secure intravenous line. To reduce pain at the injection site, a larger vein (like the antecubital vein) is preferred, and sometimes a small dose of lidocaine is administered beforehand.
• Monitoring: Continuous monitoring of heart rate, blood pressure, oxygen saturation, and end-tidal CO2 is mandatory during and after administration.

Because Etomidate is administered as a single dose or short series of doses by a healthcare professional for a specific procedure, the concept of a 'missed dose' by a patient does not apply. If a procedure is delayed, the medical team will determine the appropriate timing for administration.

An overdose of Etomidate primarily manifests as an extension of its pharmacological action.

• Signs: Severe respiratory depression (slow or stopped breathing), hypotension (low blood pressure), and prolonged unconsciousness.
• Emergency Measures: There is no specific reversal agent (antidote) for Etomidate. Treatment is supportive. This includes maintaining a patent airway, providing supplemental oxygen or mechanical ventilation, and administering intravenous fluids or vasopressors if blood pressure drops significantly. Because of the drug's rapid redistribution and metabolism, the effects of an overdose usually resolve quickly if the patient is properly supported.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Only qualified medical personnel should handle this medication.

Etomidate is associated with several common side effects that occur during or immediately after administration. While usually transient, they require management by the clinical team.

• Myoclonus (Involuntary Muscle Twitching): This is perhaps the most common side effect, occurring in up to 70% of patients who do not receive premedication. It manifests as brief, shock-like jerks of the limbs or trunk. While it looks like a seizure, it is actually caused by the disinhibition of subcortical structures in the brain. It can be minimized by pre-administering a small dose of an opioid (like fentanyl) or a benzodiazepine (like midazolam).
• Pain on Injection: Because the standard formulation contains propylene glycol, many patients experience a sharp, stinging sensation at the IV site during the injection. This occurs in approximately 20-50% of patients.
• Nausea and Vomiting: Postoperative nausea and vomiting (PONV) is common with Etomidate, occurring more frequently than with propofol. It can be distressing for the patient during recovery.

Etomidate should only be used by clinicians who are experienced in the administration of intravenous anesthetics and the management of their potential complications. Because it can cause rapid unconsciousness and potential respiratory depression, equipment for artificial airway maintenance, oxygen enrichment, and circulatory resuscitation must be immediately available.

One of the most critical safety points regarding Etomidate is its impact on the endocrine system. Patients and providers must be aware that Etomidate is a potent inhibitor of adrenal steroidogenesis. This means the body's natural ability to produce cortisol is temporarily 'turned off.' In high-stress situations like major surgery or severe infection, this can theoretically impair the body's stress response.

As of the current 2024-2026 clinical guidelines, there are no FDA black box warnings for Etomidate. It is considered a safe and effective induction agent when used as directed in appropriate clinical settings.

While there are few drugs that are strictly contraindicated for co-administration in a 'never use' sense, certain combinations are avoided due to the risk of severe CNS depression or metabolic interference.

• Ketoconazole: This antifungal medication is also a potent inhibitor of adrenal steroidogenesis. Using Etomidate and ketoconazole together can lead to profound and prolonged adrenal suppression. If a patient is on chronic ketoconazole, an alternative induction agent is often preferred.
• Other Carboxylated Imidazoles: Co-administration with similar chemical structures is generally avoided to prevent cumulative toxicity.

• CNS Depressants (Opioids, Benzodiazepines, Barbiturates): These drugs synergize with Etomidate. While they are often used together intentionally (e.g., Fentanyl given before Etomidate), the combination significantly increases the risk of apnea and hypotension. The dose of each agent should be reduced accordingly.

Conditions where Etomidate must NEVER be used include:

• Known Hypersensitivity: If a patient has a documented severe allergic reaction (anaphylaxis) to Etomidate or any of the components in the formulation (such as propylene glycol or the lipid emulsion), the drug is strictly contraindicated. The mechanism is an IgE-mediated immune response that can lead to airway collapse and shock.
• Acute Porphyria: Etomidate is considered 'porphyrinogenic.' In patients with conditions like Acute Intermittent Porphyria (AIP), the drug can induce the enzyme ALA synthase, leading to the accumulation of toxic porphyrins. This can cause severe abdominal pain, neurological damage, and psychiatric symptoms.

Conditions requiring careful risk-benefit analysis include:

Etomidate is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• Risks: Etomidate crosses the placental barrier. If used during labor or for a C-section, the concentration in the fetal blood can reach about 50% of the maternal concentration. This can lead to temporary adrenal suppression in the neonate.
• Clinical Use: It is generally reserved for pregnant patients where hemodynamic stability is paramount (e.g., a mother with severe heart disease requiring emergency surgery) and the benefits outweigh the potential risks to the fetus.

It is not known whether Etomidate is excreted in human milk. However, because the drug is rapidly cleared from the mother's system (half-life of 3-5 hours), the amount a nursing infant would receive is likely very small.

Etomidate is a GABA-A receptor agonist. Specifically, it binds to the beta-subunits of the GABA-A receptor complex in the central nervous system. This binding increases the affinity of the receptor for the inhibitory neurotransmitter GABA. When GABA binds, the chloride channel opens, chloride ions flow into the post-synaptic neuron, and the cell becomes hyperpolarized. This inhibits neuronal firing, leading to the rapid induction of a hypnotic state. Etomidate is unique because it is highly selective for these receptors and has almost no effect on other neurotransmitter systems (like NMDA or acetylcholine), which explains its lack of analgesic or muscle-relaxant properties.

• CNS Effects: Etomidate reduces the Cerebral Metabolic Rate of Oxygen (CMRO2) and reduces Cerebral Blood Flow (CBF), which leads to a decrease in Intracranial Pressure (ICP). This makes it useful for patients with head injuries.
• Cardiovascular Effects: Etomidate is noted for its 'hemodynamic neutrality.' It does not cause the release of histamine and has minimal effects on myocardial contractility (the heart's pumping strength).